{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T19:46:54Z","timestamp":1784317614692,"version":"3.55.0"},"reference-count":22,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100006087","name":"Direcci\u00f3n General de Asuntos del Personal Acad\u00e9mico, Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","award":["IN205216"],"award-info":[{"award-number":["IN205216"]}],"id":[{"id":"10.13039\/501100006087","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["N283036"],"award-info":[{"award-number":["N283036"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Immunol. Ther. Exp."],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00005-021-00615-8","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T12:17:42Z","timestamp":1619612262000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Neoantigen Cancer Vaccines: Real Opportunity or Another Illusion?"],"prefix":"10.2478","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9163-4724","authenticated-orcid":false,"given":"Karen","family":"Manoutcharian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Guzman Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goar","family":"Gevorkian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"key":"615_CR1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass E, Ott PA (2021) Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol 18:215\u2013229. https:\/\/doi.org\/10.1038\/s41571-020-00460-2","journal-title":"Nat Rev Clin Oncol"},{"key":"615_CR2","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1172\/JCI134915","volume":"130","author":"G Cafri","year":"2020","unstructured":"Cafri G, Gartner JJ, Zaks T et al (2020) mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Investig 130:5976\u20135988. https:\/\/doi.org\/10.1172\/JCI134915","journal-title":"J Clin Investig"},{"key":"615_CR3","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.1016\/j.vaccine.2011.05.007","volume":"29","author":"C Charles-Ni\u00f1o","year":"2011","unstructured":"Charles-Ni\u00f1o C, Pedroza-Roldan C, Viveros M et al (2011) Variable epitope libraries: new vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response. Vaccine 29:5313\u20135321. https:\/\/doi.org\/10.1016\/j.vaccine.2011.05.007","journal-title":"Vaccine"},{"key":"615_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01294-w","author":"RE Chen","year":"2021","unstructured":"Chen RE, Zhang X, Case JB et al (2021) Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. https:\/\/doi.org\/10.1038\/s41591-021-01294-w","journal-title":"Nat Med"},{"key":"615_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/imm.13233","volume":"161","author":"AN Dom\u00ednguez-Romero","year":"2020","unstructured":"Dom\u00ednguez-Romero AN, Mart\u00ednez-Cort\u00e9s F, Mungu\u00eda ME et al (2020) Generation of multiepitope cancer vaccines based on large combinatorial libraries of survivin-derived mutant epitopes. Immunology 161:123\u2013138. https:\/\/doi.org\/10.1111\/imm.13233","journal-title":"Immunology"},{"key":"615_CR6","doi-asserted-by":"publisher","first-page":"a028829","DOI":"10.1101\/cshperspect.a028829","volume":"10","author":"OJ Finn","year":"2018","unstructured":"Finn OJ, Rammensee HG (2018) Is it possible to develop cancer vaccines to neoantigens, what are the major challenges, and how can these be overcome? Neoantigens: nothing new in spite of the name. Cold Spring Harb Perspect Biol 10:a028829. https:\/\/doi.org\/10.1101\/cshperspect.a028829","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"615_CR7","doi-asserted-by":"publisher","first-page":"e200423","DOI":"10.1001\/jamanetworkopen.2020.0423","volume":"3","author":"A Haslam","year":"2020","unstructured":"Haslam A, Gill J, Prasad V (2020) Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs. JAMA Netw Open 3:e200423. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.0423","journal-title":"JAMA Netw Open"},{"key":"615_CR8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41591-020-01206-4","volume":"27","author":"Z Hu","year":"2021","unstructured":"Hu Z, Leet DE, Alles\u00f8e RL et al (2021) Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med 27:513\u2013525. https:\/\/doi.org\/10.1038\/s41591-020-01206-4","journal-title":"Nat Med"},{"key":"615_CR9","doi-asserted-by":"publisher","first-page":"a033704","DOI":"10.1101\/cshperspect.a033704","volume":"10","author":"HT Kissick","year":"2018","unstructured":"Kissick HT (2018) Is it possible to develop cancer vaccines to neoantigens, what are the major challenges, and how can these be overcome? Neoantigens as vaccine targets for cancer. Cold Spring Harb Perspect Biol 10:a033704. https:\/\/doi.org\/10.1101\/cshperspect.a033704","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"615_CR10","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/28860","volume":"394","author":"P Klenerman","year":"1998","unstructured":"Klenerman P, Zinkernagel RM (1998) Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 394:482\u2013485. https:\/\/doi.org\/10.1038\/28860","journal-title":"Nature"},{"key":"615_CR11","doi-asserted-by":"publisher","first-page":"23662","DOI":"10.1073\/pnas.1906026116","volume":"116","author":"GP Linette","year":"2019","unstructured":"Linette GP, Becker-Hapak M, Skidmore ZL et al (2019) Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens. Proc Natl Acad Sci USA 116:23662\u201323670. https:\/\/doi.org\/10.1073\/pnas.1906026116","journal-title":"Proc Natl Acad Sci USA"},{"key":"615_CR12","doi-asserted-by":"publisher","DOI":"10.17352\/ojpp.000011","author":"K Manoutcharian","year":"2020","unstructured":"Manoutcharian K, Valle JG, Odales J (2020) Variable epitope library-based COVID-19 vaccine for current and future related epidemics. Open J Pharmacol Pharmacother. https:\/\/doi.org\/10.17352\/ojpp.000011","journal-title":"Open J Pharmacol Pharmacother"},{"key":"615_CR13","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.cell.2017.09.050","volume":"171","author":"R Marty","year":"2017","unstructured":"Marty R, Kaabinejadian S, Rossell D et al (2017) MHC-I genotype restricts the oncogenic mutational landscape. Cell 171:1272-1283.e15. https:\/\/doi.org\/10.1016\/j.cell.2017.09.050","journal-title":"Cell"},{"key":"615_CR14","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jama.2021.2088","volume":"325","author":"JR Mascola","year":"2021","unstructured":"Mascola JR, Graham BS, Fauci AS (2021) SARS-CoV-2 viral variants-tackling a moving target. JAMA 325:1261\u20131262. https:\/\/doi.org\/10.1001\/jama.2021.2088","journal-title":"JAMA"},{"key":"615_CR15","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1093\/infdis\/jix173","volume":"215","author":"AS Monto","year":"2017","unstructured":"Monto AS, Malosh RE, Petrie JG et al (2017) The doctrine of original antigenic sin: separating good from evil. J Infect Dis 215:1782\u20131788. https:\/\/doi.org\/10.1093\/infdis\/jix173","journal-title":"J Infect Dis"},{"key":"615_CR16","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1080\/21645515.2016.1191718","volume":"12","author":"R Serv\u00edn-Blanco","year":"2016","unstructured":"Serv\u00edn-Blanco R, Zamora-Alvarado R, Gevorkian G et al (2016) Antigenic variability: obstacles on the road to vaccines against traditionally difficult targets. Hum Vaccine Immunother 12:2640\u20132648. https:\/\/doi.org\/10.1080\/21645515.2016.1191718","journal-title":"Hum Vaccine Immunother"},{"key":"615_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.imlet.2018.10.008","volume":"204","author":"R Serv\u00edn-Blanco","year":"2018","unstructured":"Serv\u00edn-Blanco R, Ch\u00e1varo-Ortiz RM, Zamora-Alvarado R et al (2018) Generation of cancer vaccine immunogens derived from major histocompatibility complex (MHC) class I molecules using variable epitope libraries. Immunol Lett 204:47\u201354. https:\/\/doi.org\/10.1016\/j.imlet.2018.10.008","journal-title":"Immunol Lett"},{"key":"615_CR18","doi-asserted-by":"publisher","first-page":"572681","DOI":"10.3389\/fcimb.2020.572681","volume":"10","author":"R Shukla","year":"2020","unstructured":"Shukla R, Ramasamy V, Shanmugam RK et al (2020) Antibody-dependent enhancement: a challenge for developing a safe dengue vaccine. Front Cell Infect Microbiol 10:572681. https:\/\/doi.org\/10.3389\/fcimb.2020.572681","journal-title":"Front Cell Infect Microbiol"},{"key":"615_CR19","doi-asserted-by":"publisher","first-page":"e2827","DOI":"10.1002\/jmr.2827","volume":"33","author":"MHV Van Regenmortel","year":"2020","unstructured":"Van Regenmortel MHV (2020) Truth in science and in molecular recognition, post-truth in human affairs. J Mol Recognit 33:e2827. https:\/\/doi.org\/10.1002\/jmr.2827","journal-title":"J Mol Recognit"},{"key":"615_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00705-020-04884-0","volume":"166","author":"MHV Van Regenmortel","year":"2021","unstructured":"Van Regenmortel MHV (2021) What does it mean to develop an HIV vaccine by rational design? Arch Virol 166:27\u201333. https:\/\/doi.org\/10.1007\/s00705-020-04884-0","journal-title":"Arch Virol"},{"key":"615_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jaut.2017.04.008","volume":"83","author":"A Vatti","year":"2017","unstructured":"Vatti A, Monsalve DM, Pacheco Y et al (2017) Original antigenic sin: a comprehensive review. J Autoimmun 83:12\u201321. https:\/\/doi.org\/10.1016\/j.jaut.2017.04.008","journal-title":"J Autoimmun"},{"key":"615_CR22","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3389\/fimmu.2017.01113","volume":"8","author":"EME Verdegaal","year":"2017","unstructured":"Verdegaal EME, van der Burg SH (2017) The potential and challenges of exploiting the vast but dynamic neoepitope landscape for immunotherapy. Front Immunol 8:1113. https:\/\/doi.org\/10.3389\/fimmu.2017.01113","journal-title":"Front Immunol"}],"container-title":["Archivum Immunologiae et Therapiae Experimentalis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00005-021-00615-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00005-021-00615-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00005-021-00615-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T20:49:32Z","timestamp":1704228572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00005-021-00615-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["615"],"URL":"https:\/\/doi.org\/10.1007\/s00005-021-00615-8","relation":{},"ISSN":["0004-069X","1661-4917"],"issn-type":[{"value":"0004-069X","type":"print"},{"value":"1661-4917","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]},"assertion":[{"value":"1 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors state no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"12"}}